经导管三尖瓣置换术的早期单中心经验
本研究报道单中心5例重度三尖瓣反流患者接受新型经导管三尖瓣置换装置(GATE系统)的同情用药经验;所有患者均成功植入,反流显著降至≤2+;基线右心室功能差与术后右心室衰竭及不良临床结局相关;4例随访3至6个月显示右心室重构、心输出量增加及纽约心脏协会功能分级改善。
要点
- 5例重度三尖瓣反流患者经导管三尖瓣置换均成功植入,反流显著降至≤2+。
- 基线右心室整体纵向应变及右心室压力变化除以时间变化差与术后右心室衰竭和不良临床结局相关。
- 4例随访3至6个月显示右心室重构、心输出量增加及纽约心脏协会功能分级改善。
核心结论
- 第一代经导管三尖瓣置换装置在重于重度三尖瓣反流的患者中技术可行,多数患者与右心室重构、心输出量增加及纽约心脏协会功能分级改善相关;需进一步研究优化患者选择并确定长期结局。
研究设计与样本
- 单中心经验,5例有症状的重度三尖瓣反流患者接受新型GATE系统经导管三尖瓣置换的同情用药;所有患者术前均行计算机断层摄影、经胸及经食管超声心动图评估三尖瓣和右心解剖;手术采用外科经心房入路,在透视和术中经食管超声心动图引导下植入瓣膜。
关键影像表现/征象
- 所有患者均成功植入经导管瓣膜,三尖瓣反流显著降至≤2+。
- 基线右心室功能差(以整体纵向应变及右心室压力变化除以时间变化衡量)与植入后右心室衰竭和不良临床结局相关。
- 4例随访3至6个月显示右心室重构、心输出量增加及纽约心脏协会功能分级改善。
局限性
- 样本量小(5例)。
- 需进一步研究优化该装置的患者选择并确定长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study presents a single-site experience of 5 patients with severe tricuspid regurgitation (TR) who underwent implantation of a novel transcatheter tricuspid valve replacement device.
BACKGROUND: Functional TR is the most common etiology of severe TR in the developed world and is associated with unfavorable clinical outcomes. Although numerous transcatheter repair devices are currently in early clinical trials, most result in incomplete degrees of TR reduction and functional improvement.
METHODS: Transcatheter tricuspid valve replacement was performed in 5 patients with compassionate use of the novel GATE System. All patients had symptomatic, massive and/or torrential TR at baseline. All patients had computed tomography, transthoracic and transesophageal echocardiographic assessment of the tricuspid valve and right heart anatomy. All patients had a surgical transatrial approach performed with valve implantation guided by fluoroscopy and intraprocedural transesophageal echocardiography.
RESULTS: Baseline characteristics of the patients showed a substantial burden of comorbidities. All patients had successful implantation of the transcatheter valve, with significant reduction of TR to ≤2+. Baseline poor right ventricular (RV) function measured by global longitudinal strain and RV change in pressure divided by change in time were associated with post-implantation RV failure and poor clinical outcomes in this small group. Four of the 5 patients were followed for 3 to 6 months following the initial implantation and showed evidence of RV remodeling, increased cardiac output, and reduction in New York Heart Association functional class.
CONCLUSIONS: Implantation of a first-generation TTVR device was technically feasible in patients with more than severe TR. Transcatheter tricuspid valve replacement was associated with RV remodeling, increased cardiac output, and improvement in New York Heart Association functional class in most patients. Further studies are needed to refine patient population selection for this device and to determine long-term outcomes.
引用
- Hahn RT, George I, Kodali SK, et al. Early Single-Site Experience With Transcatheter Tricuspid Valve Replacement. JACC Cardiovasc Imaging. 2018. PMID: 30553658. doi:10.1016/j.jcmg.2018.08.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。